Microscopic polyangiitis

Common Name(s)

Microscopic polyangiitis

Microscopic polyangiitis (MPA) is a rare disorder that causes redness and swelling (inflammation) of the small tubes that carry blood to areas of the body - specifically, small arteries (arterioles), capillaries, and small veins (venules). Inflammation of these small tubes can make them narrow, causing poor blood flow to a specific area or organ in the body. Typically, MPA affects the skin, nerves, gastrointestinal tract (esophagus, stomach and intestines), lungs and joints. The symptoms of MPA depend on which of these organ systems are affected. Symptoms may include feeling tired (fatigue), fever, weight loss, rash, joint pain, loss of appetite, cough, shortness of breath, abdominal pain, and numbness.

MPA is rare and can affect a person at any age, but usually affects people in their 40s and 50s. Your doctor can diagnose MPA based on your symptoms, a physical exam, blood tests and images (x-rays, MRI or CT) of the affected area. In some cases, removal and examination of the affected area (biopsy) may be needed to confirm the diagnosis. Some people with MPA will have a positive blood test, known as antineutrophil cytoplasmic antibody (ANCA). However, not everyone with MPA will have a positive ANCA.

Treatment of MPA depends on which tissue or organs are affected and may include medications that control your immune system (immunosuppressive medications) or that treat the inflammation (steroids). The goal of treatment is to stop the inflammation (remission) and to keep it from coming back (maintain remission). However, even after MPA is treated and a person is in remission, symptoms can still return (relapse or flare). If you have been diagnosed with MPA, talk to your doctor to discuss the most current treatment options. Support groups are a good source of additional information.

Source: Advocacy organizations associated with the condition.

 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Microscopic polyangiitis" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Microscopic polyangiitis" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Microscopic polyangiitis" returned 100 free, full-text research articles on human participants. First 3 results:

The influence of the Great East Japan earthquake on microscopic polyangiitis: A retrospective observational study.
 

Author(s): Yoichi Takeuchi, Ayako Saito, Yoshie Ojima, Saeko Kagaya, Hirotaka Fukami, Hiroyuki Sato, Ken Matsuda, Tasuku Nagasawa

Journal:

 

Antineutrophil cytoplasmic antibody-associated vasculitis is triggered by environmental factors, including silica dust exposure. Repeated tsunami waves brought a large volume of silica-containing sludge inland after the Great East Japan earthquake in 2011. We aimed to determine if ...

Last Updated: 12 May 2017

Go To URL
Microscopic polyangiitis and non-HBV polyarteritis nodosa with poor-prognosis factors: 10-year results of the prospective CHUSPAN trial.
 

Author(s): Maxime Samson, Xavier Puéchal, Luc Mouthon, Hervé Devilliers, Pascal Cohen, Boris Bienvenu, Kim Heang Ly, Alain Bruet, Brigitte Gilson, Marc Ruivard, Edouard Pertuiset, Mohamed Hamidou, Christian Pagnoux, Benjamin Terrier, Loïc Guillevin,

Journal: Clin. Exp. Rheumatol.. ;35 Suppl 103(1):176-184.

 

To analyse the 10-year outcomes of 64 patients with non-HBV polyarteritis nodosa (PAN) or microscopic polyangiitis (MPA) and Five-Factor Score-defined poor-prognosis factors enrolled (1994-2000) in the prospective, randomised, open-label CHUSPAN trial.

Last Updated: 19 Apr 2017

Go To URL
Successful Immunosuppressive Treatment of Mixed Connective Tissue Disease Complicated by Microscopic Polyangiitis.
 

Author(s): Shuzo Sato, Makiko Yashiro, Naoki Matsuoka, Manabu Uematsu, Tomoyuki Asano, Hiroko Kobayashi, Hiroshi Watanabe, Hiromasa Ohira

Journal: Tohoku J. Exp. Med.. 2016 06;239(2):111-6.

 

Mixed connective tissue disease (MCTD) is characterized by a combination of clinical features of systemic lupus erythematosus, systemic sclerosis, and polymyositis with elevated antibodies to U1 small nuclear ribonucleoprotein (U1-RNP). MCTD is often accompanied by interstitial lung ...

Last Updated: 30 May 2016

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Microscopic polyangiitis" returned 9 free, full-text review articles on human participants. First 3 results:

Current therapy of granulomatosis with polyangiitis and microscopic polyangiitis: the role of rituximab.
 

Author(s): Duvuru Geetha, Cees Kallenberg, John H Stone, Alan D Salama, Gerald B Appel, George Duna, Paul Brunetta, David Jayne

Journal: J. Nephrol.. 2015 Feb;28(1):17-27.

 

Granulomatosis with polyangiitis and microscopic polyangiitis are anti-neutrophil cytoplasmic antibody-associated vasculitides (AAVs) that are prone to cycles of remission and relapse. The introduction of cytotoxic therapy has changed the prognosis for these diseases from typically ...

Last Updated: 16 Apr 2015

Go To URL
Cyclophosphamide as induction therapy for Wegener's granulomatosis and microscopic polyangiitis.
 

Author(s): C A Langford

Journal: Clin. Exp. Immunol.. 2011 May;164 Suppl 1():31-4.

 

The introduction of cyclophosphamide (CyP) as a treatment for Wegener's granulomatosis (WG) and microscopic polyangiitis (MPA) has been among the most significant contributions in vasculitis. Prior to the introduction of CyP, WG was a uniformly fatal disease, with mortality occurring ...

Last Updated: 30 Mar 2011

Go To URL
Microscopic polyangiitis.
 

Author(s): Sharon A Chung, Philip Seo

Journal: Rheum. Dis. Clin. North Am.. 2010 Aug;36(3):545-58.

 

In 1923, Friedrich Wohlwill described two patients with a "microscopic form of periarteritis nodosa," which was distinct from the classical form. This disease, now known as microscopic polyangiitis (MPA), is a primary systemic vasculitis characterized by inflammation of the small-caliber ...

Last Updated: 6 Aug 2010

Go To URL
 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Longitudinal Protocol for Granulomatosis With Polyangiitis (Wegener's) and Microscopic Polyangiitis
 

Status: Recruiting

Condition Summary: Granulomatosis With Polyangiitis; Microscopic Polyangiitis; Wegener's

 

Last Updated: 21 Feb 2017

Go to URL

Last Updated: 11 Jul 2017

Go to URL
Pharmacokinetic Study of Rituximab Induction Regimen in ANCA-associated Vasculitis
 

Status: Recruiting

Condition Summary: Granulomatosis, Wegener's; Microscopic Polyangiitis

 

Last Updated: 20 Jan 2017

Go to URL